EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

INDIANAPOLIS, June 16, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab) exhibited either no progres... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news